Seeking Alpha
10 Jun 2026, 08:43 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Top 2 movers · tap to explore
What the story claims
2 claims · each scored for market impact
Cogstate is aggressively expanding its clinical trial growth by targeting new indications, specifically focusing on psychiatry and narcolepsy. — Expansion into high-demand therapeutic areas like psychiatry increases the addressable market and potential for long-term revenue growth.
+0.60The company is focusing on scaling its solution expansion to drive adoption across more clinical trials. — Broader solution adoption suggests a move toward becoming a standard tool in clinical research, improving scalability.
+0.40Which stocks this story touches
The company is discussing growth strategies and expansion into new clinical trial indications.
Continue reading
6 related stories
Go deeper
You just saw which tickers this one story hits. A free account turns that into a standing screen: the movers delivered on schedule, before the chart catches up.
On this page · free
In the platform
Free account, 30 seconds. No credit card. Covers all 10 tickers this story moves.
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Screener bridge
Catch the names this kind of story moves — before the chart does.
Get the full NIS Momentum results every Friday at 4PM ET — free via email or Telegram.
Seeking Alpha
10h ago
